104 related articles for article (PubMed ID: 2585396)
21. Intraperitoneal cisplatin and carboplatin in the management of ovarian cancer.
Markman M
Semin Oncol; 1994 Apr; 21(2 Suppl 2):17-9; quiz 20, 58. PubMed ID: 8202717
[TBL] [Abstract][Full Text] [Related]
22. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel.
Ozols RF; Bookman MA; du Bois A; Pfisterer J; Reuss A; Young RC
Gynecol Oncol; 2006 Oct; 103(1):1-6. PubMed ID: 16904166
[No Abstract] [Full Text] [Related]
23. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.
Walker JL; Armstrong DK; Huang HQ; Fowler J; Webster K; Burger RA; Clarke-Pearson D
Gynecol Oncol; 2006 Jan; 100(1):27-32. PubMed ID: 16368440
[TBL] [Abstract][Full Text] [Related]
24. Intravenous chemotherapy, early debulking surgery, and consolidation intraperitoneal chemotherapy in advanced ovarian carcinoma.
Tournigand C; Louvet C; Molitor JL; Dehni N; Lejeune V; Sezeur A; Pigne A; Marpeau L; Cady J; de Gramont A
Gynecol Oncol; 2001 Nov; 83(2):198-204. PubMed ID: 11606072
[TBL] [Abstract][Full Text] [Related]
25. A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma.
Gershenson DM; Morris M; Burke TW; Levenback C; Wolf J; Lee JJ; Thall PF; Atkinson EN; Silva EG; Wharton JT
Cancer; 1999 Dec; 86(11):2291-300. PubMed ID: 10590370
[TBL] [Abstract][Full Text] [Related]
26. [Significance and effects of intraperitoneal cisplatin administration for ovarian cancer].
Shimizu A; Ookubo K; Hasegawa J; Endoh T; Fujiwara O; Yoda A; Okuyama D; Narabayashi A; Kimura T; Takahashi J; Notake Y
Gan To Kagaku Ryoho; 1999 Oct; 26(12):1801-5. PubMed ID: 10560398
[TBL] [Abstract][Full Text] [Related]
27. [Intraperitoneal administration of high doses of cisplatin in advanced ovarian carcinoma].
Ptácková B; Kopecný J; Zatocil P; Anton M
Cesk Gynekol; 1989 Mar; 54(2):106-9. PubMed ID: 2731237
[TBL] [Abstract][Full Text] [Related]
28. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest.
Gadducci A; Carnino F; Chiara S; Brunetti I; Tanganelli L; Romanini A; Bruzzone M; Conte PF
Gynecol Oncol; 2000 Feb; 76(2):157-62. PubMed ID: 10637064
[TBL] [Abstract][Full Text] [Related]
29. Complications relating to intraperitoneal administration of cisplatin or carboplatin for ovarian carcinoma.
Sakuragi N; Nakajima A; Nomura E; Noro N; Yamada H; Yamamoto R; Fujimoto S
Gynecol Oncol; 2000 Dec; 79(3):420-3. PubMed ID: 11104613
[TBL] [Abstract][Full Text] [Related]
30. Contrast media induced irreversible acute renal failure in a patient treated with intraperitoneal cisplatin.
Oymak O
Clin Nephrol; 1995 Aug; 44(2):135-6. PubMed ID: 8529307
[No Abstract] [Full Text] [Related]
31. Intraperitoneal chemotherapy as treatment for ovarian carcinoma and gastrointestinal malignancies: the Memorial Sloan-Kettering Cancer Center experience).
Markman M; Reichman B; Hakes T; Hoskins W; Rubin S; Jones W; Lewis JL
Acta Med Austriaca; 1989; 16(3-4):65-7. PubMed ID: 2609915
[TBL] [Abstract][Full Text] [Related]
32. Clinical and pharmacokinetic study of intraperitoneal cisplatin at two dose levels: 100 mg/m2 alone or 200 mg/m2 with i.v. sodium thiosulfate.
Canal P; de Forni M; Chatelut E; Chevreau C; Johnson NP; Houin G; Bugat R
Acta Med Austriaca; 1989; 16(3-4):84-6. PubMed ID: 2609919
[TBL] [Abstract][Full Text] [Related]
33. Cisplatin and cyclophosphamide in early epithelial ovarian carcinoma.
Chiara S; Conte PF; Bruzzone M; Falcone A; Sertoli MR; Carnino F; Mossetti C; Iura R; Durando C; Guercio E
Chemioterapia; 1987 Oct; 6(5):380-3. PubMed ID: 3427698
[TBL] [Abstract][Full Text] [Related]
34. Ovarian carcinoma: the role of chemotherapy.
Thigpen JT; Vance RB; Lambuth BW
Semin Oncol; 1988 Jun; 15(3 Suppl 3):16-23. PubMed ID: 3293214
[TBL] [Abstract][Full Text] [Related]
35. [Ovarian carcinoma: surgery and polychemotherapy with cisplatin. Considerations on a clinical case].
Moresco L; Quidaciolu F; Ingravaglieri E; Sorice G
Chir Ital; 1983 Feb; 35(1):71-6. PubMed ID: 6687313
[TBL] [Abstract][Full Text] [Related]
36. Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot.
van der Vange N; van Goethem AR; Zoetmulder FA; Kaag MM; van de Vaart PJ; ten Bokkel Huinink WW; Beijnen JH
Eur J Surg Oncol; 2000 Nov; 26(7):663-8. PubMed ID: 11078613
[TBL] [Abstract][Full Text] [Related]
37. [The value of platinum dose intensity in first-line therapy on subsequent disease follow-up of epithelial ovarian carcinoma].
Gruböck K
Wien Klin Wochenschr; 1994; 106(11):362-6. PubMed ID: 8053205
[No Abstract] [Full Text] [Related]
38. Second line platinum-based intraperitoneal chemotherapy for advanced ovarian cancer.
Milczek T; Klasa-Mazurkiewicz D; Emerich J; Kobierski J
Acta Obstet Gynecol Scand; 2009; 88(4):463-7. PubMed ID: 19235559
[TBL] [Abstract][Full Text] [Related]
39. High dose cisplatin after failure of polychemotherapy containing cisplatin in ovarian cancer. Preliminary results.
Bruzzone M; Conte PF; Chiara S; Carnino F; Giaccone G; Conio A; Bentivoglio G; Pescetto G; Rosso R
Chemioterapia; 1985 Apr; 4(2):139-42. PubMed ID: 3891114
[TBL] [Abstract][Full Text] [Related]
40. Intraperitoneal alpha-interferon alternating with cisplatin in residual ovarian carcinoma: a phase II Gynecologic Oncology Group study.
Berek JS; Markman M; Blessing JA; Kucera PR; Nelson BE; Anderson B; Hanjani P
Gynecol Oncol; 1999 Jul; 74(1):48-52. PubMed ID: 10385550
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
